361 Preventing signaling by ANGPTL2, which is stimulated by the tumor microenvironment, could inhibit metastasis.
http://stke.sciencemag.org/cgi/content/abstract/sigtrans;7/309/ra7
360 Large-scale genomic analysis of somatic point mutations in exomes from tumour–normal pairs across 21 cancer types identifies most known cancer genes in these tumour types as well as 33 genes not known to be significantly mutated, and down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies.
http://www.nature.com/nature/journal/v505/n7484/full/nature12912.html
359 Alterations in the Microbiota Drive Interleukin-17C Production from Intestinal Epithelial Cells to Promote Tumorigenesis.
http://www.cell.com/immunity/abstract/S1074-7613(13)00557-8
358 Barcoding technology enabled measurement of hundreds of cellular proteins from cancer patients with single-cell resolution.
http://stm.sciencemag.org/content/6/219/219ra9.abstract
357 Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells.
http://www.sciencemag.org/content/343/6168/301.abstract
356 The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins.
http://www.sciencemag.org/content/343/6168/305.abstract
355 Bioengineered Bacterial Outer Membrane Vesicles as Cell-Specific Drug-Delivery Vehicles for Cancer Therapy.
http://pubs.acs.org/doi/abs/10.1021/nn405724x
354 Preventing the cleavage of the TGFβ type I receptor by presenilin 1 could limit prostate tumor growth.
http://stke.sciencemag.org/cgi/content/abstract/sigtrans;7/307/ra2
353 Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma.
http://www.sciencemag.org/content/343/6167/189.abstract
352 microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition.
http://www.nature.com/ncomms/2014/140107/ncomms3977/full/ncomms3977.html
351 Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.
http://www.nature.com/neuro/journal/v17/n1/abs/nn.3597.html
350 Inactivating CUX1 mutations promote tumorigenesis.
http://www.nature.com/ng/journal/v46/n1/abs/ng.2846.html
349 Self-renewal as a therapeutic target in human colorectal cancer.
http://www.nature.com/nm/journal/v20/n1/abs/nm.3418.html
348 Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression.
http://stm.sciencemag.org/content/6/217/217ra3.abstract
347 Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice.
http://stm.sciencemag.org/content/6/217/217ra2.abstract
346 Collective Invasion in Breast Cancer Requires a Conserved Basal Epithelial Program.
http://www.cell.com/abstract/S0092-8674(13)01480-3
345 Mutant KRAS is a druggable target for pancreatic cancer.
http://www.pnas.org/content/110/51/20723.abstract
344 CD13-positive bone marrow-derived myeloid cells promote angiogenesis, tumor growth, and metastasis.
http://www.pnas.org/content/110/51/20717.abstract
343 Ascites analysis by a microfluidic chip allows tumor-cell profiling.
http://www.pnas.org/content/110/51/E4978.abstract
342 p53 status determines the role of autophagy in pancreatic tumour development.
http://www.nature.com/nature/journal/v504/n7479/full/nature12865.html
|
